Han-Kuang Biotechnology is developing a new drug, HCB101, which targets the CD47 molecule. This drug utilizes AI-assisted protein engineering to overcome previous safety and efficacy challenges, aiming to selectively attack tumor cells without harming red blood cells. The company plans to pursue international licensing after completing proof-of-concept for HCB101. AI
IMPACT AI is enabling targeted therapies in drug discovery, potentially accelerating the development of safer and more effective treatments.
RANK_REASON The item describes a novel drug development using AI, which falls under research. [lever_c_demoted from research: ic=1 ai=1.0]
Read on Mastodon — fosstodon.org →
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
